S
ince the Zika flavivirus was introduced into Brazil, it has spread across Central and South America and the Caribbean, fueled by widespread distribution of the Aedes aegypti vector and a susceptible human population (1) . Zika virus infection has been associated with Guillain-Barré syndrome in adults, congenital birth defects (including microcephaly, vision-threatening ocular lesions, and central nervous system lesions), and fetal death (2) (3) (4) (5) . Despite the vector-control measures already implemented in many affected countries to combat dengue and yellow fever, Zika continued to spread throughout 2016 and into 2017 (6) . Sustained reduction of risk for future outbreaks will likely require a combination of vector control and vaccination, as is necessary for yellow fever, another flavivirus (7) . Zika vaccine development has progressed quickly, benefiting from existing technologies underlying other flavivirus vaccines (8) . A viable vaccine is expected to be available in the next several years (9) .
A vaccine's effectiveness in preventing infections depends not only on its efficacy but also on demographic and fertility patterns, local Zika attack rates, and the proportion of the population still susceptible when it becomes available. Supplies may initially be insufficient to cover the entire population. In this case, vaccine supply should be allocated to minimize infections in pregnant women because perinatal transmission to infants has the gravest consequences. The World Health Organization (WHO) has proposed prioritizing females aged 9 to 49 years, followed by males aged 9 to 49 years, for receipt of Zika vaccine (10, 11) . Although women in the peak of their fertility years are a clear priority during an outbreak, how to extend vaccination to other women and to men is less clear. This is particularly challenging when the likely timing of an outbreak is uncertain.
Previous models have projected that up to 93.4 million people, including 1.65 million pregnant women, would be infected during the first epidemic wave in the Americas (12) . A predictive model has suggested that herd immunity from the first epidemic wave could provide up to a decade of protection against future epidemics (13) . Other forecasts have warned that Zika could become sylvatic in parts of the Americas, including Brazil, which would pose a continual reintroduction threat (14) . These studies also warned that Zika outbreaks could be exacerbated by cross-interaction with dengue vaccination (15) . To evaluate the potential for vaccination to reduce future transmission of Zika virus, we developed an age-stratified model applied in each of 34 affected countries and territories. By accounting for country-specific demographics, vector abundance, and potential sexual transmission, we evaluated the effectiveness of Zika vaccination for averting prenatal infections.
METHODS

Model Overview
We developed a compartmental model of Zika transmission, incorporating both vector-borne and sexual transmission. Susceptible men and women are at risk for becoming asymptomatically exposed to Zika by vector-borne or sexual routes, from which they become infectious. Infectiousness to mosquitoes lasts between 4 and 7 days (16) . After this phase, women recover but men remain infectious to their female partners for an additional 15 to 180 days (17) . Immunologic protection is conferred on recovery or via vaccination and is assumed to be robust, consistent with other flaviviruses (18, 19) . Each of these clinical and epidemiologic states (susceptible, exposed, infected, recovered, or vaccinated) is stratified by age and sex. We accounted for age-specific fertility, which is fundamental to accurately estimating prenatal infection risk, and background agespecific mortality. Mosquito vectors are susceptible to Zika infection, are latently infected, or are infectious to humans. As our primary outcome, we quantified the burden of an epidemic as the predicted prenatal Zika incidence, measured as infections per 1000 pregnancies over 5 years. A model flow chart and equations describing the system are in Part 1 of the Supplement (available at Annals.org).
Transmission
We assumed that symptomatic and asymptomatic infection are equally infectious. We also assumed frequency-dependent, homogeneous transmission between humans and mosquitoes and no waning of natural immunity, consistent with other flaviviruses (18, 19) . We modeled sexual transmission by incorporating ageand sex-specific rates of partnership formation and mixing matrixes, which define the probability of sexual contact between men and women for every age combination (Supplement Tables 1 and 2 , available at Annals.org) (20 -22) . Immune persons will neither acquire nor transmit infections even if exposed in the future, thereby reducing the overall transmission rate and indirectly protecting susceptible persons through herd immunity.
Vaccination
We simulated vaccination by calculating the number of persons who would be vaccinated within each age and sex group (as determined by the planned coverage for that group) and moving these persons from the susceptible to the vaccinated group before the epidemic (Supplement Figure 1 , available at Annals.org). We analyzed vaccination strategies in the following 5 groups: females aged 9 to 49 years (the WHO target product profile), both sexes aged 9 to 49 years, single 5-year age cohorts of females between ages 10 and 49 years, only males aged 9 to 49 years, and scale-up beginning with the 5-year age cohorts in the third strategy and expanding in 5-year age increments.
Vaccination of Females Aged 9 to 49 Years
To quantify the effect of vaccination according to the WHO target product profile on prenatal infections (11), we modeled coverage ranging from 0% to 90% of females aged 9 to 49 years.
Vaccination of Population Aged 9 to 49 Years
As a secondary strategy, we extended coverage to include 0% to 90% of both males and females aged 9 to 49 years.
Age-Specific Vaccination Effect
To quantify the effect of age-specific vaccination, we compared vaccination of women in each 5-year age group between ages 15 and 49 years. For each coun- 
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try, we also tested the correlation between the agespecific fertility rate and prenatal infections averted per dose using a simple linear regression.
Indirect Protection
To quantify the indirect protection conferred by vaccinating the nonchildbearing population, we simulated the reduction in prenatal infections achieved by vaccinating only males aged 9 to 49 years.
Vaccination Scale-up
To determine how a limited supply of vaccines should be allocated, we modeled the effect of vaccinating each possible contiguous age group, constrained by age breaks at 5-year intervals (ages 10 to 14 years, 10 to 19 years, and so on up to 10 to 49 years, followed by 15 to 19 years, 15 to 24 years, and so forth). We then plotted the prenatal infections averted and vaccines administered under each scenario and determined the age groups for which targeted vaccination dominates (that is, averts at least as many infections as all other strategies that use as many or more vaccine doses). From this set of dominant strategies, we first identified the 5-year age group with the optimal vaccination effect per dose. We then identified the next 3 age groups expanding on this optimal age group.
Countries and Territories
We modeled Puerto Rico, the U.S. Virgin Islands, and the following 32 countries: Aruba, Barbados, Belize, Bolivia, Bonaire, Brazil, Colombia, Costa Rica, Cuba, Curacao, Dominica, Dominican Republic, Ecuador, El Salvador, French Guiana, Guadeloupe, Guatemala, Guyana, Haiti, Honduras, Jamaica, Martinique, Mexico, Nicaragua, Panama, Paraguay, Saint Lucia, Saint Martin, Saint Vincent and the Grenadines, Suriname, Trinidad and Tobago, and Venezuela (23).
Human Demographics
For each country, we constructed annual age groups from birth to 100 years among males and females, initialized the population distribution, and parametrized region-and age-specific fertility and mortality rates from United Nations data (Supplement Tables 3 to 6, available at Annals.org).
Mosquito Population
For each region, we calibrated the mosquito birth rate to align the model equilibrium mosquito prevalence with empirical estimates (Supplement Table 7 , available at Annals.org) and incorporated seasonal fluctuations in mosquito abundance (24) . For countries in which mosquito prevalence indexes were unavailable, we substituted estimates from geographically proximate countries. Because we did not evaluate vector control, we did not include A aegypti pupal or larval development in the model.
Vaccine Efficacy
We assumed a base-case vaccine efficacy of 75% as a midpoint within the recommended minimal and Projections assume the best-fit attack rate and 90% coverage with a vaccine of 75% efficacy. Evaluating Vaccination Strategies for Zika Virus in the Americas ORIGINAL RESEARCH preferred vaccine efficacies of 70% and 80%, respectively, designated in the WHO target product profile for Zika vaccine (25) .
Parameter Calibration
Mortality and biting rates for A aegypti and Zikaspecific parameter estimates were drawn from published literature (Supplement Tables 7 and 8 , available at Annals.org). We calibrated the model in a 3-step process. First, we fixed the mosquito-to-human Zika transmission rate relative to the human-to-mosquito transmission rate, as estimated in previous models of Zika in the Americas (12, 26) . Second, we varied the human-tomosquito transmission rate and simulated the corresponding Zika epidemics. On the basis of projections of decade intervals between Zika outbreaks due to herd immunity (13), we used a 10-year horizon. Third, we determined the best-fit parameter sets for the epidemiologic variables using a least-squares approach. For Puerto Rico, we computed the human-to-mosquito transmission rate that produced a 23.5% attack rate, as observed during the chikungunya outbreak there (27) , and computed the mosquito seasonality parameters that best fit the observed Zika epidemic trajectory from 17 January 2016 through 21 July 2017 (Supplement Figure 3 , available at Annals.org) (28, 29) . When not otherwise specified, we used the best-fit attack rate for Puerto Rico as our base case. Given the uncertainty about these rates in many countries, we did a sensitivity analysis in which we varied the attack rate from 5% to 50% for each country (Supplement Table 9 , available at Annals.org).
Sensitivity Analysis
To quantify how preexisting immunity acquired during Zika outbreaks before vaccine availability affects vaccine effectiveness, we varied the percentage of the population immune to Zika from 0% to 50% while varying the attack rate from 5% to 50% and modeling 0%, 50%, and 90% coverage of females aged 9 to 49 years. To evaluate the sensitivity of vaccination scale-up to uncertainty in outbreak timing, we considered a scenario where an outbreak starts 10 years after vaccination (13) . The decrease in vaccination effectiveness under retracted coverage represented in this sensitivity analysis also approximates the effect of reducing vaccine efficacy.
Statistical Analysis
We fit our model to Puerto Rican incidence data using a Bayesian melding approach. To incorporate empirical parameter uncertainty into model projections, we first used Monte Carlo sampling to create 5000 input parameter sets from prior distributions for epidemiologic, clinical, entomologic, demographic, and age-specific fertility derived from empirical ranges for each parameter (Supplement Figure 2 , available at Annals.org). We then selected the 1000 parameter sets that, for Puerto Rico, generated a cumulative Zika attack rate that minimized the mean square difference from the observed chikungunya attack rate of 23.5%. Finally, with each of these 1000 parameter sets, and separately for each country, we compared the effect of vaccinating females aged 9 to 49 years versus both females and males aged 9 to 49 years.
Role of the Funding Source
The funding source had no role in the study design; collection, analysis, or interpretation of data; writing the report; or the decision to publish the manuscript.
RESULTS
In each of the 34 countries and territories considered, we predicted the effect on prenatal infections of vaccinating females aged 9 to 49 years, and then of expanding coverage to include males in this age group, consistent with the WHO target population (11 1 and 2) . Extending coverage to include 90% of males aged 9 to 49 years would have averted all but 76 prenatal infections (CrI, 52 to 111 infections), achieving an overall reduction of 99% (CrI, 98% to 99%). 
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In regions that have had a Zika outbreak, a fraction of the population will have immunity. For example, if 25% of the population in Puerto Rico is already immune to Zika (27) , coverage of 50% or 90% of women aged 9 to 49 years would reduce prenatal infections in a subsequent outbreak to 5 or 2, respectively, per 1000 pregnancies ( Figure 3, middle and right) , compared with 192 infections in an unvaccinated, immunologically naive Puerto Rican population (Figure 3, left) . The expected effect under reduced vaccine coverage in this sensitivity analysis also approximates the effect under reduced vaccine efficacy.
In case vaccine supply does not permit coverage across the full age range recommended by the WHO, we compared the effectiveness of vaccinating each 5-year age group between the ages of 10 and 49 years. For all countries and age groups, the estimated number of prenatal infections averted per administered vaccine was significant (P < 0.001) in proportion to the country-and age-specific fertility rate ( Figure 4 and Supplement Figure 5 ; linear regression in Supplement Figure 6 , available at Annals.org). For most countries, including Brazil, Costa Rica, and Puerto Rico, vaccinating women aged 20 to 24 years is most effective. For some countries, such as Dominica, Guadeloupe, and Suriname, fertility typically peaks later, such that vaccinating women aged 25 to 34 years is predicted to achieve the greatest reduction in prenatal Zika infections.
We found that optimal vaccination strategiesthose preventing more prenatal infections than other strategies for the same number of vaccine doses-first target female age groups with the highest childbearing rates and then sequentially expand to other age groups as more vaccine becomes available ( Figure 5) . In Puerto Rico, the most efficient strategy is to vaccinate women aged 20 to 24 years, followed by 20 to 29 years, and then successively extend vaccination to contiguous age groups, alternating between older and younger groups. It becomes efficient to vaccinate males only after all females younger than 49 years have been vaccinated. We found that the 4 age groups in which vaccination has the greatest effect encompass women aged 20 to 34 years in all 34 regions evaluated ( Figure 6 ). For countries with a higher mean age of childbearing, such as Haiti, optimal vaccination also includes women aged 35 to 39 years, whereas for countries with a lower mean age of childbearing, such as the Dominican Republic, optimal vaccination includes women aged 15 to 19 years. The magnitude of the decrease in marginal benefit varies considerably more. For example, the numbers of infections averted by the first and third age groups differ by 37% in Barbados and 56% in Jamaica. If an outbreak is not expected immediately, vaccination in older age groups has less relative effect and the priority shifts to younger women (Figure 6, right) .
DISCUSSION
Our results indicate that a vaccine against Zika virus, once available and effectively deployed, may substantially reduce prenatal infections. However, the magnitude of this reduction is sensitive to local demographics, transmission potential, and outbreak timing. To maximize vaccination effect per dose in regions with high probability of an outbreak in the near future, vaccines should generally be provided first to women in their 20s. Then, as more vaccine becomes available, coverage should be expanded to include all women aged 15 to 39 years. Our marginal benefit analysis identified the four 5-year age groups in which vaccination has the greatest effect for each country ( Figure 6) . A country's mean age of childbearing is the primary determinant of optimal strategy. Secondarily, demographic structure and sexual contact patterns influence the optimum strategy. The first 3 priority groups comprise ages 20 to 34 years in all but 1 region evaluated. The exception, the Dominican Republic, has the lowest mean age of childbearing, which leads to prioritization of women aged 15 to 19 years before those aged 30 to 34 years. The fourth 5-year extension includes women aged 35 to 39 years for 13 of the countries with a relatively high mean age of childbearing, such as Haiti. For all other countries, optimal vaccination extends to women aged 15 to 19 years. The shift in optimal policy occurs between Saint Lucia and Aruba, at mean childbearing ages of 27.7 and 28.0 years, respectively, with the exception of Bonaire and Dominica. Attack rates and preexisting immunity both range from 0% to 50%. Results are shown for a vaccine of 75% efficacy in Puerto Rico; results for other countries are in Supplement Figure 4 (available at Annals.org).
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Our results underscore the importance of understanding the interplay between human demography and the epidemiologic dynamics of the Zika virus when control and immunization strategies are being developed. In particular, previous models suggest that herd immunity from the current epidemic could delay future outbreaks for up to a decade (13) . Our analysis shows that the coverage required to control future epidemics of Zika depends on the age-specific pattern of preexisting immunity at the time a vaccine becomes available. Consequently, seroprevalence surveys across the affected countries will be critical both in understanding the extent of the current epidemic and for future planning.
An estimated 1.65 million pregnant women (CrI, 1.45 million to 2.06 million women) in the Americas were infected with Zika during the 2015 to 2016 outbreak (12), consistent with our estimate of 1.85 prenatal infections. A third analysis predicted 7800 prenatal infections (CrI, 5900 to 10 300 infections) for Puerto Rico (31), which is higher than our estimate of 5530 prenatal infections (CrI, 3551 to 7503 infections), although the CrIs overlap. The discrepancy likely arises from different parameterization of the cumulative attack rates. The attack rate in the previous analysis was based on an outbreak of chikungunya in Puerto Rico. However, data from the entire course of the Zika outbreak have since become available, which we incorporated in conjunction with age-specific fertility to improve accuracy. Based on these estimates, the expected burden of Zika congenital syndrome (ZCS) would be 127 to 221 cases for our prediction and 180 to 312 cases for the previous estimate, assuming a 2.3% to 4% risk per completed pregnancy (30) . As of 5 October 2017, only 47 cases had been reported (32). 
Females
Males and Females
Dominant strategies, which avert at least as many infections as all other strategies using equal or more vaccines, are indicated with the corresponding age group labeled. Results are for Puerto Rico, assuming a 75% vaccine efficacy.
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Several sources of bias could explain this discrepancy and affect estimated risk for ZCS given prenatal infection (33) . Bias could arise from underreporting, misdiagnosis, or disproportionate rates of pregnancy termination among infected women. A confounding factor may also have elevated the risk for birth defects from Zika. Previous dengue exposure has been suggested to heighten the risk for Zika complications (34) , and both viruses were circulating in Brazil (15) during the time in which we estimated ZCS risk. Given the uncertainties of the association between ZCS risk and prenatal infection, we projected incidence and prenatal infections rather than ZCS cases. The outcome measure of prenatal infections can also be translated to risks for other ZCS manifestations that may still be identified. The affinity of Zika virus for the central nervous system may lead to more subtle but nonetheless significant cognitive or neurologic impairments that are less immediately apparent than such manifestations as microcephaly. Zika infection has been preliminarily linked with neuropsychological and cognitive changes in adolescents (35) . Likewise, the flavivirus chikungunya has been shown to cause neurocognitive impairments among young children, as well as prolonged arthralgia and depression (36, 37) .
Uncertainties remain about other clinical and epidemiologic aspects of Zika. Lifelong immunity is generally expected on the basis of immune responses to other flaviviruses (38). However, longitudinal serologic studies will be necessary to quantify immunologic protection and waning. In vitro studies have suggested cross-reactivity between dengue and Zika antibodies (39) , but the effect of this cross-reactivity on clinical outcomes remains unclear (40, 41) . When country-specific Figure 6 . The optimal 5-y age group for vaccination and the marginal benefit of further expansions in coverage in 5-y increments, under a 25% attack rate and 75% vaccine efficacy for an outbreak occurring immediately after vaccination (left) or 10 y after vaccination (right). Evaluating Vaccination Strategies for Zika Virus in the Americas ORIGINAL RESEARCH parameters for age-stratified sexual mixing were not available, we used U.S.-derived estimates (Supplement Table 2 ); when country-specific mosquito indexes were not available, we used estimates from geographically proximate countries (Supplement Table 7) . As with any model, we made several simplifying assumptions. Our model is based on a compartmental framework, in which the population is divided into distinct groups representing clinical Zika status (susceptible, exposed, infected, recovered, and vaccinated), stratified by age and sex. This framework is appropriate given the data available and high-level focus on country outcomes. An alternative approach is an agentbased structure, which typically tracks individuals in a population. Agent-based modeling is generally most suitable when stochasticity of individual-level human behavior affects epidemiologic outcomes (such as during disease emergence and eradication) and when individual-level data are available for parameterization. Although our results do not capture local heterogeneity in incidence of Zika infection, our model does highlight the robustness of targeted vaccination strategies across affected countries.
The Aedes mosquitoes that transmit Zika have long been the target of vector-control measures in affected regions. We therefore assumed that the effect of vector control on mosquito density would remain constant throughout the period of projections. The appropriate vaccine strategy to deploy under any improvements in vector control, such as more aggressive efforts or the introduction of genetically modified Wolbachia (42, 43) , can be determined by considering the lower attack rate scenarios in our sensitivity analyses. Likewise, longterm shifts in mosquito prevalence, as might be driven by climate change, could be represented by varying the attack rates (44, 45) .
Significant challenges must be addressed in the development and implementation of a Zika vaccine. The decrease in Zika incidence makes traditional methodology for clinical trials infeasible. Even during an epidemic, the speed of Zika outbreaks at the local level necessitates innovative approaches for trial site selection, possibly including simultaneous preapproval and surveillance for many sites. At the implementation stage, cost-effectiveness and affordability are key considerations in the resource-constrained settings at highest risk for Zika outbreaks. Further research is required to elucidate regional patterns of age-stratified Zika seroprevalence, which could affect the cost-effectiveness of vaccination in different countries.
Despite these challenges, our results show the substantial effect that Zika vaccination programs could have in mitigating and preventing future outbreaks. Through a combination of direct protection and indirect reduction of transmissions, virtual elimination is achievable even with imperfect vaccine efficacy and coverage. Our results also highlight the importance of targeted Zika vaccination. Given the temporal uncertainty of Zika resurgences, we must continue to develop and test vaccines, ensuring availability as soon as possible.
